List view / Grid view
All five pre-symptomatic babies with spinal muscular atrophy (SMA) were…
All five pre-symptomatic babies with spinal muscular atrophy (SMA) were able to swallow and feed orally after 12 months of treatment.
The Phase II study of Evrysdi showed significant improvements in…
The Phase II study of Evrysdi showed significant improvements in survival and motor milestones in babies with type 1 spinal muscular atrophy (SMA).
The European Commission has granted marketing authorisation to Roche’s Evrysdi™…
The European Commission has granted marketing authorisation to Roche’s Evrysdi™ (risdiplam) as a treatment for spinal muscular atrophy in infants, children and adults.
